Document Detail


Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
MedLine Citation:
PMID:  16126016     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In a recent multinational, double-blind, placebo-controlled, randomized, phase III study (BONE: IBandronate Osteoporosis Vertebral Fracture trial in North America and Europe), oral daily ibandronate (2.5 mg) significantly and substantially reduced the risk of new vertebral fractures by 62% relative to placebo after 3 years of treatment. The objective of the present study was to retrospectively analyze data from the BONE study to examine the efficacy of oral ibandronate in preventing incident vertebral fractures of greater severity. This analysis was conducted on the placebo and oral daily ibandronate (2.5 mg) arms of the BONE study, comprising a total of 1964 women (aged 55-80 years, >or=5 years postmenopause) with osteoporosis. Vertebral fractures on annual lateral radiographs of the spine were graded as mild, moderate, or severe, using criteria derived from an established semiquantitative technique. The findings demonstrate that in addition to being effective in significantly reducing the risk of new vertebral fractures of all severities, oral daily ibandronate has a pronounced effect on the more severe, most clinically relevant, vertebral fractures: a significant and sustained reduction of 59% in the relative risk of combined new moderate and severe vertebral fractures was observed at years 1 (P = 0.0164), 2 (P = 0.0004), and 3 (P < 0.0001).
Authors:
D Felsenberg; P Miller; G Armbrecht; K Wilson; R C Schimmer; S E Papapoulos
Related Documents :
19995486 - Vertebral compression fractures--new clinical signs to aid diagnosis.
3135096 - Changes in incidence and prevalence of vertebral fractures during 30 years.
19430876 - Translational aspects of bone quality--vertebral fractures, cortical shell, microdamage...
19465166 - Bone creep can cause progressive vertebral deformity.
10755426 - Acute compartment syndrome. who is at risk?
16908396 - What is new in the treatment of steroid-induced osteoporosis?
Publication Detail:
Type:  Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2005-08-25
Journal Detail:
Title:  Bone     Volume:  37     ISSN:  8756-3282     ISO Abbreviation:  Bone     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-10-24     Completed Date:  2006-01-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8504048     Medline TA:  Bone     Country:  United States    
Other Details:
Languages:  eng     Pagination:  651-4     Citation Subset:  IM    
Affiliation:
Charité-University Medicine Berlin, Campus Benjamin Franklin, Centre of Muscle and Bone Research, Hindenburgdamm 30, Berlin 12200, Germany. dieter.felsenberg@charite.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aged
Aged, 80 and over
Bone Density Conservation Agents / administration & dosage,  adverse effects,  therapeutic use*
Diphosphonates / administration & dosage,  adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Double-Blind Method
Europe
Female
Humans
Incidence
Internationality
Lumbar Vertebrae / injuries*
Middle Aged
North America
Osteoporosis, Postmenopausal / complications,  drug therapy*
Risk
Severity of Illness Index
Spinal Fractures / epidemiology,  etiology,  prevention & control*
Time Factors
Chemical
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Diphosphonates; 114084-78-5/ibandronic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Do serological tissue turnover markers represent callus formation during fracture healing?
Next Document:  Diet, lifestyle, and nonstatin trials: review of time to benefit.